Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents is expected to continue its positive growth trend as they have had stable quarterly revenue and modest full-year growth, with a focus on improving gross margins through increased efficiency and continued regulatory progress for their key product DrugSorb-ATR. Management's approach of prioritizing process clarity over speed should reduce the risk of further regulatory hurdles and maintain a strong outlook for the company. With a strong focus on improving key applications of their proprietary blood purification technologies, CytoSorbents is poised for continued success in the USA, Germany, and other markets.

Bears say

CytoSorbents is facing declining sales in their core market in Germany, and while they attribute this to restructuring, there is no guarantee of sustained stabilization. Additionally, the company's cash balance of $7.8M highlights the need for successful execution of cost reduction and inventory normalization in order to reach their stated objective of a break even point in the second half of the year. The company's reliance on international sales to support growth and diversify their revenue stream also presents a risk in the face of potential economic and political disruptions.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.